Personalized Antiplatelet Therapy Following Endovascular Revascularization in Peripheral Artery Occlusive Disease: A Novel Concept

EJVES Short Reports

Volumn 29, Issue , 2015, Pages 11-17

  Peeters Weem, S M O ^a   Leunissen, T C ^a   Teraa, M ^a,b   Vonken, E J ^a   De Borst, G J ^a   Moll, F L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b University Medical Center Utrecht ^*  (Netherlands)

Author keywords

Antiplatelet therapy; Dual antiplatelet therapy; Endovascular interventions; Personalized antiplatelet therapy; Platelet reactivity testing; Thrombocyte aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL;

ADD ON THERAPY; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; DEEP VEIN THROMBOSIS; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; FOLLOW UP; HUMAN; ILIAC ARTERY STENT; INTERMITTENT CLAUDICATION; KIDNEY TRANSPLANTATION; LEG REVASCULARIZATION; LOADING DRUG DOSE; LUNG EMBOLISM; MALE; MECHANICAL THROMBECTOMY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERSONALIZED MEDICINE; PLATELET REACTIVITY; PRIORITY JOURNAL; SELF EXPANDING STENT; SUPERFICIAL FEMORAL ARTERY; SUPERFICIAL FEMORAL ARTERY STENT; THROMBECTOMY CATHETER; THROMBUS ASPIRATION;

EID: 84953883867     PISSN: None     EISSN: 24056553     Source Type: Journal    
DOI: 10.1016/j.ejvssr.2015.09.003     Document Type: Article

References (28)

1. L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, and F.G. Fowkes Inter-society consensus for the management of peripheral arterial disease (TASC ii) J Vasc Surg 45 Suppl. S 2007 S5 S67
2. E. Tetteroo, Y. van der Graaf, J.L. Bosch, A.D. van Engelen, M.G. Hunink, B.C. Eikelboom, and et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch iliac stent trial study group Lancet 351 1998 1153 1159
3. A.T. Hirsch, Z.J. Haskal, N.R. Hertzer, C.W. Bakal, M.A. Creager, J.L. Halperin, and et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease Circulation 113 2006 e463 654
4. P. Kougias, A. Chen, C. Cagiannos, C.F. Bechara, T.T. Huynh, and P.H. Lin Subintimal placement of covered stent versus subintimal balloon angioplasty in the treatment of long-segment superficial femoral artery occlusion Am J Surg 198 2009 645 649
5. T. Zeller, A. Rastan, R. Macharzina, G. Tepe, M. Kaspar, J. Chavarria, and et al. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions J Endovasc Ther 21 2014 359 368
6. M. Bosiers, K. Deloose, J. Callaert, N. Moreels, K. Keirse, J. Verbist, and et al. Results of the protege everflex 200 mm long nitinol stent (EV3) in TASC C and D femoropopliteal lesions J Vasc Surg 54 2011 1042 1050
7. G.M. Ansel, and A.B. Lumsden Evolving modalities for femoropopliteal interventions J Endovasc Ther 16 2009 II82 97
8. J.M. Davaine, L. Azema, B. Guyomarch, P. Chaillou, A. Costargent, P. Patra, and et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) c and d femoropopliteal lesions (the STELLA "stenting long de l'artere femorale superficielle" cohort) Eur J Vasc Endovasc Surg 44 2012 432 441
9. L. Robertson, M.A. Ghouri, and F. Kovacs Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment Cochrane Database Syst Rev 8 2012 CD002071
10. M.T. Allemang, R.R. Rajani, P.R. Nelson, A. Hingorani, and V.S. Kashyap Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures Ann Vasc Surg 27 2013 62 67
11. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, M.K. Natarajan, and et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-cure study Lancet 358 2001 527 533
12. S.J. Brener, S.R. Steinhubl, P.B. Berger, D.M. Brennan, and E.J. Topol Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the credo trial J Invas Cardiol 19 2007 287 290
13. S.R. Steinhubl, P.B. Berger, J.T. Mann 3rd, E.T. Fry, A. DeLago, C. Wilmer, and et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial JAMA 288 2002 2411 2420
14. P. Alonso-Coello, S. Bellmunt, C. McGorrian, S.S. Anand, R. Guzman, M.H. Criqui, and et al. Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence based clinical practice guidelines Chest 141 2012 e669S e690S
15. A. Vyas, R. El Accaoui, A. Blevins, and W. Karrowni Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis Postgrad Med 126 2014 176 186
16. P.P. Wisman, M. Roest, F.W. Asselbergs, P.G. de Groot, F.L. Moll, Y. van der Graaf, and et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis J Thromb Haemost 12 2014 736 747
17. S. Spiliopoulos, G. Pastromas, A. Diamantopoulos, and K. Katsanos Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures Expert Opin Pharmacother 15 2014 2205 2217
18. M. Droppa, D. Tschernow, K.A. Muller, E. Tavlaki, A. Karathanos, F. Stimpfle, and et al. Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (predict-stable) PLoS One 10 2015 e0121620
19. T.C. Leunissen, G.J. De Borst, P.W. Janssen, and J.M. Ten Berg The role of peri-operative antiplatelet therapy and platelet reactivity testing in carotid revascularization: overview of the evidence J Cardiovasc Surg 56 2015 165 175
20. D. Sibbing, S. Schulz, S. Braun, T. Morath, J. Stegherr, J. Mehilli, and et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement J Thromb Haemost 8 2010 250 256
21. T. Cuisset, G. Cayla, C. Frere, J. Quilici, R. Poyet, B. Gaborit, and et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5 2009 325 329
22. M.J. Price, P.B. Berger, P.S. Teirstein, J.F. Tanguay, D.J. Angiolillo, D. Spriggs, and et al. Standard- vs. high dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the gravitas randomized trial JAMA 305 2011 1097 1105
23. G. Montalescot, G. Range, J. Silvain, J.L. Bonnet, Z. Boueri, O. Barthelemy, and et al. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the arctic study Circulation 129 2014 2136 2143
24. J.M. Siller-Matula, M. Francesconi, C. Dechant, B. Jilma, G. Maurer, G. Delle-Karth, and et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the Madonna study Int J Cardiol 167 2013 2018 2023
25. X.D. Wang, D.F. Zhang, S.W. Zhuang, and Y. Lai Modifying clopidogrel maintenance doses according to vasodilator-stimulated phosphoprotein phosphorylation index improves clinical outcome in patients with clopidogrel resistance Clin Cardiol 34 2011 332 338
26. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, O. Wittenberg, and et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 2008 1404 1411
27. M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, A. Furgieri, and et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study Circulation 119 2009 3215 3222
28. J.M. Siller-Matula, and B. Jilma Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost 110 2013 628 631